American CryoStem to Collaborate With Rutgers University on Adipose-Derived Stem Cell Research
14 Mai 2013 - 2:30PM
American CryoStem Corporation (OTCQB:CRYO), a
leading strategic developer, marketer and global licensor of
patented adipose tissue-based and cellular technologies for the
Regenerative and Personalized Medicine industries, today announced
that it has entered into Material Transfer Agreements with three
leading research scientists at Rutgers, The State University of New
Jersey, distinguished as one of the world's premier universities
for stem cell research and training.
American CryoStem has teamed with Kathryn Uhrich, PhD, Professor
and Dean, Mathematical & Physical Sciences; KiBum Lee, PhD,
Assistant Professor of Chemistry & Chemical Biology; and
Prabhas Moghe, PhD, Professor and Vice-Chair of Biomedical
Engineering and Professor of Chemical and Biochemical Engineering,
all of whom will be utilizing the Company's autologous
Adipose-Derived Stem Cells (ADSCs) and patented, serum free, GMP
grade, cell culture and differentiation mediums to research,
develop and commercialize innovative new cellular therapies
addressing the $5 billion global wound care market.
"American CryoStem was founded in New Jersey in 2008, completed
its initial research and development work in New Jersey, and built
its FDA-registered tissue laboratory in the Burlington County
College (BCC) High Technology and Life Science Incubators, where we
perfected and validated our proprietary and patented technologies,"
John S. Arnone, CEO of American CryoStem, said. "Rutgers was
the next logical step for development and expansion of our cellular
therapy products. We are very proud to be collaborating with
the State's top bio-tech academic research institution and to be
part of the global development of cellular therapies."
The initial stage of collaboration with Rutgers University will
provide for Drs. Uhrich, Lee and Moghe to identify, understand and
publish their findings on engineered biomaterial interaction with
adipose-derived stem cells, the Company's cell culture media and
the resulting tissue growth when used in the treatment of chronic
or hard-to-heal wounds, such as diabetic and pressure
ulcers. American CryoStem developed and patented a new cell
culture medium for growing human stromal cells (including all cells
found in human skin, fat and other connective tissue) that is
animal product free and suitable for human clinical and therapeutic
uses. Future stages of collaboration will focus on testing and
data collection with a goal of progressing to clinical studies and
trials with an end result of the commercialization of effective,
new cellular therapy products.
Anthony Dudzinski, COO of American CryoStem, noted, "Rutgers'
intellectual resources and extensive research experience in the
field of Regenerative Medicine, coupled with our Company's
proprietary technologies and expertise with adipose-derived stem
cells, provide a powerful combination of skill, knowledge and a
common mission – to advance the study, development and
commercialization of exciting new stem cell therapies that are
capable of effectively treating human illnesses and diseases."
The Rutgers-American CryoStem interactions were conceived by
Dr. Kathryn Uhrich, the Dean of the Mathematical
and Physical Sciences at the Rutgers School of Arts of
Sciences. Dr. Uhrich is widely recognized as one of the
leading innovators in polymer research. She is engaged in the study
of the synthesis and characterization of biocompatible polymers for
medical and dental applications, such as drug delivery and tissue
engineering.
Dr. KiBum Lee obtained his PhD in Chemistry
from the Northwestern University and completed his postdoctoral
research in stem cell biology at the Scripps Research Institute.
His primary research interest is in developing and integrating
nanotechnologies and chemical functional genomics to modulate
signaling pathways in cells (e.g. stem cells and cancer cells)
towards specific cell lineages or behaviors.
Dr. Prabhas Moghe is a leading expert in stem
cell bioengineering and profiling cell-biomaterial
interactions. An International Fellow of Biomaterials Science
and Engineering, he has directed a NSF funded IGERT Program on Stem
Cell Science and Engineering, the first of its PhD training program
in the USA and continues to direct a NIH CORE resource center on
polymeric biomaterials on high content imaging technologies to
purify and forecast stem cell fates in complex
microenvironments. Dr. Moghe's team will investigate and
benchmark stromal cell phenotypes in three-dimensional
biomaterials.
About American CryoStem Corporation
A pioneer in the fields of Regenerative and Personalized
Medicine, American CryoStem is a developer, marketer and global
licensor of patented adipose tissue-based cellular technologies and
related proprietary services with a focus on clinical processing,
commercial bio-banking and application development for adipose
(fat) tissue and autologous adipose-derived regenerative cells
(ADRCs). The Company maintains a strategic portfolio of
intellectual property and patent applications that form its Adipose
Tissue Processing Platform, which supports and promotes a growing
pipeline of biologic products and processes, clinical services and
international licensing opportunities. Through its ACS
Laboratories division, the Company operates an FDA registered, cGMP
compliant human tissue processing, cryo-storage, cell culture and
differentiation media development facility in Mount Laurel, New
Jersey. For more information, please visit
www.americancryostem.com and
www.acslaboratories.com.
This press release may contain forward-looking statements,
including information about management's view of American CryoStem
Corporation's ("the Company") future expectations, plans and
prospects. In particular, when used in the preceding
discussion, the words "believes," "expects," "intends," "plans,"
"anticipates," or "may," and similar conditional expressions are
intended to identify forward-looking statements. Any
statements made in this press release other than those of
historical fact, about an action, event or development, are
forward-looking statements. These statements involve known and
unknown risks, uncertainties and other factors, which may cause the
results of the Company, its subsidiaries and concepts to be
materially different than those expressed or implied in such
statements. Unknown or unpredictable factors also could have
material adverse effects on the Company's future results. The
forward-looking statements included in this press release are made
only as of the date hereof. The Company cannot guarantee
future results, levels of activity, performance or
achievements. Accordingly, you should not place undue reliance
on these forward-looking statements. Finally, the Company
undertakes no obligation to update these statements after the date
of this release, except as required by law, and also takes no
obligation to update or correct information prepared by third
parties that are not paid for by American CryoStem Corporation.
CONTACT: Hanover|Elite
Kathy Addison or Dodi Handy
407-585-1080 or via email at
CRYO@hanoverelite.com
American Cryostem (CE) (USOTC:CRYO)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
American Cryostem (CE) (USOTC:CRYO)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024